新闻

8月 31, 2020

Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.

Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.

“I am very excited to welcome Dr. Yining Qi onboard as our Executive Vice President, Frontage Laboratories and President of Frontage Greater China Region”, said Dr. Song Li, CEO of Frontage Laboratories. “Dr. Qi’s extensive experiences in both pharmaceutical companies and CRO businesses make him ideally suited to lead Frontage Greater China District’s operations. We have confidence in his leadership to grow Frontage’s business.”

戚亦宁先生于药品监管、药物研发及CRO领域拥有近30年的行业经验。在加入方达之前，戚亦宁先生曾担任河北常山生化药业股份有限公司研发/药政医学事务副总裁及研究院院长，中美冠科全球高级营运副总裁、中美冠科太仓公司总经理，太仓冠科分析检测有限公司董事长、总经理。在此之前，戚亦宁先生还曾就职于多家跨国药企和CRO公司并担任多项职务，包括担任药明康德（苏州）技术运营、客户服务及项目管理执行总监，默沙东药物研发实验室(MRL)运营经理和首席研究员，美国BD公司(Becton, Dickinson and Company)临床运营主管/DBA，北京药监局药品检验所药理和毒理研究室主任。                                  

戚亦宁先生于2007年获美国罗格斯大学药厂管理专业工商管理硕士学位，于1999年获美国东南大学计算机科学理学硕士学位，于1991年获山西医科大学公共卫生硕士学位，并于1984年获山西医科大学医学学士学位。                                                                

“加入方达科技是我的荣幸和荣幸，”齐博士说。 “我相信我过去的研发和管理经验将进一步帮助提升方达为制药公司和研发机构提供优质高效服务的能力。”